Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
110 hedge funds and large institutions have $110M invested in Antares Pharma, Inc. in 2017 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 29 increasing their positions, 36 reducing their positions, and 13 closing their positions.
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
7% more funds holding
Funds holding: 103 → 110 (+7)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
19% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 36
37% less capital invested
Capital invested by funds: $176M → $110M (-$65.4M)
59% less call options, than puts
Call options by funds: $46K | Put options by funds: $112K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.4M |
| 2 |
BC
Broadfin Capital
New York
|
+$2.89M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$1.09M |
| 4 |
TF
TIAA FSB
Jacksonville,
Florida
|
+$1.07M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$556K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4.75M |
| 2 |
Two Sigma Investments
New York
|
-$1.48M |
| 3 |
PA
Perceptive Advisors
New York
|
-$1.32M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$1.05M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$913K |
ATRS Hedge Fund Activity: Q4 2017 in Review
110 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2017, worth a combined $110M — down 37% from $176M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new ATRS positions and 13 closed out — a net gain of 8 holders — while 29 added to existing stakes and 36 trimmed.
The largest buyer was Armistice Capital, adding an estimated $7.4M. The largest seller was Renaissance Technologies, cutting an estimated $4.75M.
- 110 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2017, up from 103 in Q3 2017.
- Funds reported $110M of Antares Pharma, Inc. stock for Q4 2017, down 37% quarter-over-quarter.
- 21 funds opened new Antares Pharma, Inc. positions in Q4 2017 and 13 closed out, a net change of +8 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2017 was Armistice Capital, an estimated $7.4M added.
- The largest Antares Pharma, Inc. seller in Q4 2017 was Renaissance Technologies, an estimated $4.75M sold.
Based on aggregated 13F filings for Q4 2017.